Endometrioid epithelial ovarian cancer

Abstract

BACKGROUND. Clinicopathological features and outcome of women with endometrioid and serous ovarian adenocarcinoma were compared. METHODS. Between 1984 and 2004, baseline and follow‐up data were prospectively recorded on 1545 patients with ovarian cancer. Of these, 270 had pure endometrioid tumors; 659 had pure serous adenocarcinoma of the ovary. Response to platinum‐based chemotherapy (PBC) overall survival, stage‐for‐stage median progression‐free survival (PFS), and cause‐specific median survival were compared. Independent predictors of survival were examined by using multivariate analyses. RESULTS. Median age of diagnosis for patients with endometrioid tumors was younger than those with serous adenocarcinoma of the ovary (60 years vs 62 years; P = .013). They presented more often with early disease (stage I and II; 50% vs 17%; P < .001), had less ascites, and had better performance status both overall and for stage II and III disease. More endometrioid tumors were optimally debulked overall (71% vs 45%; P < .001), but there was no difference according to stage. Objective and CA125 PBC response rates were not significantly different, but median PFS was better for patients with endometrioid tumors (24 months vs 13 months; P < .0001) as was overall median survival (48 months vs 22 months; P < .0001). This relation remained for stage II and III disease and for moderately and poorly differentiated tumors. Patients with concurrent endometrioid ovarian and endometrial malignancies had a survival advantage compared with those with ovarian malignancies alone. Independent predictors of survival after PBC were histological type, debulking status, and disease stage. CONCLUSIONS. Despite similar PBC response rates, endometrioid histology is associated with better survival compared with serous adenocarcinoma of the ovary, even with stage III or poorly differentiated tumors. Cancer 2008. © 2008 American Cancer Society.

Clinicopathological Perspectives on Endometrioid Epithelial Ovarian Carcinoma in Indian Women

“…Thirteen percent cases were well-differentiated tumours and the rest were either moderately or poorly differentiated which correlates well with other studies. Studies in the published literature differ on the prognostic importance of tumour grade as a predictor of survival [2,16]. Tumour grade was not an independent predictor of survival in our study.…”

“…FIGO stage was an important predictor of survival, with advanced stage on presentation leading to poorer prognosis, like in other studies [2] (Fig. 1).…”

“…The median age at diagnosis was 50 years, which is lower than the 60 years for endometrioid epithelial ovarian carcinoma mentioned in other studies [2].…”

“…Endometrioid ovarian cancer has been estimated to account for 10-12 % of all epithelial ovarian cancers [1,2]. Unlike the high-grade serous subtypes of ovarian cancer, endometrioid epithelial ovarian cancer arises from a different molecular pathway and is more likely to present at an early stage, with well-differentiated histology [3].…”

Low membranous expression of β-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary

“…1,2 Some studies have showed that the endometrioid histology is associated with a better outcome than the serous histology. [2][3][4] In contrast, other studies have shown that when patients with endometrioid and serous tumors of the ovary are matched for age, tumor grade, disease stage, and level of cytoreduction, there is no difference in either the rate of 5-year survival or the mean/median length of survival. 5 The most commonly used grading systems have been those of the International Federation of Gynecology and Obstetrics (FIGO), the World Health Organization (WHO), and the Gynecologic Oncology Group (GOG).…”